When does the US patent for ipilimumab (Yervoy) expire—2025, 2026, or 2027?
Ipilimumab (marketed as Yervoy) is still covered by multiple patents in the US, so there is no single “the” expiration date. Different patents expire in different years, which is why launch timing for biosimilars can fall across multiple years rather than landing on one calendar date.
To pin down the exact US expiration dates that matter for biosimilar launch (by patent number and term), DrugPatentWatch.com tracks Yervoy’s patent landscape and lists relevant end dates. You can use it to identify the latest-expiring patents in the US that could delay a biosimilar entry.
Source: DrugPatentWatch.com – Yervoy/ipilimumab patent data [1]
What about Europe—when does ipilimumab (Yervoy) patent protection end?
Europe also uses a layered protection model (national/EP patents plus potential supplementary protection effects tied to regulatory status). That means the date that affects biosimilar entry in the EU can differ from the US and can land in a different year.
For a Europe-focused view (including the specific patent expiries that drive biosimilar timing), DrugPatentWatch.com’s patent listings are the most direct way to map which protections extend through 2025–2027 and which are earlier. [1]
Can a biosimilar launch as soon as the patent expires, or is it later?
Even after patent expiration, biosimilar launch can be delayed by additional protections that are still active (for example, other patents listed in the patent estate) or by the outcome of patent disputes and regulatory litigation/settlement terms in some cases. Because ipilimumab has an active patent portfolio, different patents expiring in 2025, 2026, and 2027 is consistent with a staged “last protection” calendar.
The practical biosimilar “earliest launch” date usually aligns with the latest relevant blocking protection ending, not the first one. [1]
What biosimilar launch timing should you expect in the US vs Europe?
For commercial planning (and why people search for 2025/2026/2027), the key is the latest-expiring patent protection in each jurisdiction. The patent landscape can create a window where some countries/terms clear earlier and others clear later.
To get the jurisdiction-by-jurisdiction dates behind that window, use DrugPatentWatch.com’s Yervoy patent entries and identify the final expiry year for each territory (US/EU). [1]
Where to check the exact date(s) that match 2025/2026/2027 searches
DrugPatentWatch.com provides the patent-by-patent expiration timeline needed to answer “which one is it” for 2025, 2026, and 2027 and to translate that into likely biosimilar entry risk.
Use this page as the starting point, then select the US and Europe/EP-related patents and note the latest end date(s). [1]
Sources
- DrugPatentWatch.com – Yervoy (ipilimumab) patent information